173 related articles for article (PubMed ID: 34898589)
1. What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience.
Liontos M; Svarna A; Theofanakis C; Fiste O; Andrikopoulou A; Kaparelou M; Koutsoukos K; Thomakos N; Haidopoulos D; Rodolakis A; Dimopoulos MA; Zagouri F
Curr Oncol; 2021 Nov; 28(6):4862-4873. PubMed ID: 34898589
[TBL] [Abstract][Full Text] [Related]
2. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
3. Uterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases.
Black C; Feng A; Bittinger S; Quinn M; Neesham D; McNally O
Int J Gynecol Cancer; 2016 Jan; 26(1):133-40. PubMed ID: 26588230
[TBL] [Abstract][Full Text] [Related]
4. Comparison of outcomes in early-stage uterine clear cell carcinoma and serous carcinoma.
Zhang M; Yang TJ; Desai NB; DeLair D; Kollmeier MA; Makker V; Leitao MM; Abu-Rustum NR; Alektiar KM
Brachytherapy; 2019; 18(1):38-43. PubMed ID: 30316723
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy versus primary cytoreductive surgery for stage IV uterine serous carcinoma.
Wilkinson-Ryan I; Frolova AI; Liu J; Stewart Massad L; Thaker PH; Powell MA; Mutch DG; Hagemann AR
Int J Gynecol Cancer; 2015 Jan; 25(1):63-8. PubMed ID: 25365590
[TBL] [Abstract][Full Text] [Related]
6. Trends in Treatment of Uterine Serous Cancer in the Medicare Population.
Rauh-Hain JA; Connor SC; Clemmer JT; Foley OW; Clark RM; Hall TR; Boruta DM; Schorge JO; del Carmen MG
Int J Gynecol Cancer; 2015 Jul; 25(6):1023-30. PubMed ID: 25914960
[TBL] [Abstract][Full Text] [Related]
7. An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers.
Vogel TJ; Knickerbocker A; Shah CA; Schiff MA; Isacson C; Garcia RL; Goff BA
J Gynecol Oncol; 2015 Jan; 26(1):25-31. PubMed ID: 25376917
[TBL] [Abstract][Full Text] [Related]
8. Early-stage Uterine Pure and Mixed Clear Cell Carcinoma: Outcomes and Recurrence With and Without Adjuvant Therapy.
Chang-Halpenny CN; Natarajan S; Hwang-Graziano JM
Am J Clin Oncol; 2018 Apr; 41(4):371-378. PubMed ID: 26950465
[TBL] [Abstract][Full Text] [Related]
9. Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma.
Vaidya AP; Horowitz NS; Oliva E; Halpern EF; Duska LR
Gynecol Oncol; 2006 Nov; 103(2):684-7. PubMed ID: 16797683
[TBL] [Abstract][Full Text] [Related]
10. Uterine serous carcinoma.
Bogani G; Ray-Coquard I; Concin N; Ngoi NYL; Morice P; Enomoto T; Takehara K; Denys H; Nout RA; Lorusso D; Vaughan MM; Bini M; Takano M; Provencher D; Indini A; Sagae S; Wimberger P; Póka R; Segev Y; Kim SI; Candido Dos Reis FJ; Lopez S; Mariani A; Leitao MM; Raspagliesi F; Panici PB; Di Donato V; Muzii L; Colombo N; Scambia G; Pignata S; Monk BJ
Gynecol Oncol; 2021 Jul; 162(1):226-234. PubMed ID: 33934848
[TBL] [Abstract][Full Text] [Related]
11. Clinical Significance of Positive Pelvic Washings in Uterine Papillary Serous Carcinoma Confined to an Endometrial Polyp.
Hanley KZ; Fadare O; Fisher KE; Atkins KA; Mosunjac MB
Int J Gynecol Pathol; 2016 May; 35(3):249-55. PubMed ID: 26535985
[TBL] [Abstract][Full Text] [Related]
12. Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).
Goldberg H; Miller RC; Abdah-Bortnyak R; Steiner M; Yildiz F; Meirovitz A; Villà S; Poortmans PM; Azria D; Zidan J; Ozsahin M; Abacioglu U; Gold DG; Amit A; Lavie O; Atahan IL; Kuten A;
Gynecol Oncol; 2008 Feb; 108(2):298-305. PubMed ID: 18096209
[TBL] [Abstract][Full Text] [Related]
13. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.
Menderes G; Clark M; Santin AD
Discov Med; 2016 Apr; 21(116):293-303. PubMed ID: 27232515
[TBL] [Abstract][Full Text] [Related]
14. Role of Adjuvant Therapy for Stage IA Serous and Clear Cell Uterine Cancer: Is Observation a Valid Strategy?
Velker V; D'Souza D; Prefontaine M; McGee J; Leung E
Int J Gynecol Cancer; 2016 Mar; 26(3):491-6. PubMed ID: 26825823
[TBL] [Abstract][Full Text] [Related]
15. National patterns of care and cancer-specific outcomes of adjuvant treatment in patients with serous and clear cell endometrial carcinoma.
Xiang M; English DP; Kidd EA
Gynecol Oncol; 2019 Mar; 152(3):599-604. PubMed ID: 30551884
[TBL] [Abstract][Full Text] [Related]
16. Stage IA uterine serous carcinoma: a study of 13 cases.
Carcangiu ML; Tan LK; Chambers JT
Am J Surg Pathol; 1997 Dec; 21(12):1507-14. PubMed ID: 9414196
[TBL] [Abstract][Full Text] [Related]
17. Uterine superficial serous carcinomas and extensive serous endometrial intraepithelial carcinomas: clinicopathological analysis of 6 patients.
Ono K; Hayashi H; Tateno M; Tanaka R; Suzuki R; Maruyama Y; Miyagi Y; Furuya M
Int J Clin Exp Pathol; 2014; 7(11):7979-88. PubMed ID: 25550841
[TBL] [Abstract][Full Text] [Related]
18. Optimal surgical debulking in uterine papillary serous carcinoma affects survival.
Patsavas K; Woessner J; Gielda B; Rotmensch J; Yordan E; Bitterman P; Guirguis A
Gynecol Oncol; 2011 Jun; 121(3):581-5. PubMed ID: 21440290
[TBL] [Abstract][Full Text] [Related]
19. [Precursor lesions of type II endometrial cancer: diagnostic criteria and pathogenesis].
Wang HJ; Zheng WX
Zhonghua Bing Li Xue Za Zhi; 2007 Aug; 36(8):505-7. PubMed ID: 17980094
[No Abstract] [Full Text] [Related]
20. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.
Fader AN; Roque DM; Siegel E; Buza N; Hui P; Abdelghany O; Chambers SK; Secord AA; Havrilesky L; O'Malley DM; Backes F; Nevadunsky N; Edraki B; Pikaart D; Lowery W; ElSahwi KS; Celano P; Bellone S; Azodi M; Litkouhi B; Ratner E; Silasi DA; Schwartz PE; Santin AD
J Clin Oncol; 2018 Jul; 36(20):2044-2051. PubMed ID: 29584549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
